Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Core Growth Allocation ETF (AOR) vs Merck & Co., Inc. (MRK) Price & Performance

iShares Core Growth Allocation ETFTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

iShares Core Growth Allocation ETF vs Merck & Co., Inc. — how do they compare? iShares Core Growth Allocation ETF trades at $69.87, while Merck & Co., Inc. trades at $130.29 (market cap $323.00B). The key difference: Merck & Co., Inc. pays a 2.6% dividend while iShares Core Growth Allocation ETF pays none. Which is the better fit depends on your goals.

AORMRK
52-Week High
$70.12$131.84
52-Week Low
$62.26$77.60
Market Cap
$323.00B
Sector
Health
Enterprise Value
$369.77B
Dividend Yield
2.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Core Growth Allocation ETF

AOR, the iShares Core Growth Allocation ETF, trades at $70.12, up 0.57% on the day, with a bullish technical signal driven by moving averages. The ETF maintains a fixed 60/40 stock/bond allocation, rebalances semiannually, and offers low-cost exposure with a 0.20% fee. Recent news highlights its role as a core holding but notes long-term underperformance versus the S&P 500 over the past decade.

The outlook for AOR hinges on its diversified asset allocation strategy providing stability, though it faces risks from equity and fixed income market volatility. Its simplicity appeals to investors seeking a hands-off approach, but competition from pure equity funds and interest rate sensitivity are key considerations for potential returns.

Merck & Co., Inc.

MRK trades at $130.90, up 1.81% today, with a bullish technical signal and strong institutional buying interest. The stock shows robust fundamentals with revenue of $65.01B in 2025 and net income of $18.25B, though a high P/E of 104.74 indicates premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.

Outlook is positive with a consensus price target of $139.90, offering ~7% upside, supported by 67.57% analyst buy ratings. Risks include integration challenges from acquisitions and patent expirations, but strong cash flow and dividend payments provide stability. Investors may find value in Merck's market leadership and pipeline expansion, though valuation metrics warrant caution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares Core Growth Allocation ETF

The fund is a fund of funds and seeks its investment objective by investing primarily in underlying funds that themselves seek investment results corresponding to their own respective underlying indexes. It generally will invest at least 80% of its assets in the component securities of its underlying index. The index measures the performance of the S&P Dow Jones Indices LLC proprietary allocation model.

Read more on AOR

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK